Next Article in Journal
Clinical Relevance of Vaginal Cuff Dehiscence after Minimally Invasive versus Open Hysterectomy
Previous Article in Journal
Perinatal and Maternal Outcomes According to the Accurate Term Antepartum Ultrasound Estimation of Extreme Fetal Weights
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 12
Issue 8
10.3390/jcm12082996
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Heart Valve Involvement in Patients with Antiphospholipid Syndrome: A Long-Term Follow-Up Study of a Single Centre

by
Isaac Pons
1,2,3,
Joana Louro
1,2,
Marta Sitges
2,4,5,
Bàrbara Vidal
2,4,5,
Ricard Cervera
1,2,* and
Gerard Espinosa
1,2
1
Department of Autoimmune Diseases, Reference Centre (UEC/CSUR) for Systemic Autoimmune Diseases of the Catalan and Spanish Health Systems, Hospital Clínic, Universitat de Barcelona, 08036 Barcelona, Spain
2
Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain
3
Department of Internal Medicine, Althaia Xarxa Assistencial Universitària de Manresa, Facultat de Medicina, Universitat de Vic-Universitat Central de Catalunya (UVic-UCC), 08240 Manresa, Spain
4
Institut Clínic Cardiovascular (ICCV), Hospital Clínic, Universitat de Barcelona, 08036 Barcelona, Spain
5
Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2023, 12(8), 2996; https://doi.org/10.3390/jcm12082996
Submission received: 28 March 2023 / Revised: 15 April 2023 / Accepted: 17 April 2023 / Published: 20 April 2023
(This article belongs to the Section Cardiology)
Browse Figures
Versions Notes

Abstract

:
Background: Valve involvement is the most common cardiac manifestation in antiphospholipid syndrome (APS). The objective of the study was to describe the prevalence, clinical and laboratory features, and evolution of APS patients with heart valve involvement. Methods: A retrospective longitudinal and observational study of all APS patients followed by a single centre with at least one transthoracic echocardiographic study. Results: 144 APS patients, 72 (50%) of them with valvular involvement. Forty-eight (67%) had primary APS, and 22 (30%) were associated with systemic lupus erythematosus (SLE). Mitral valve thickening was the most frequent valve involvement present in 52 (72%) patients, followed by mitral regurgitation in 49 (68%), and tricuspid regurgitation in 29 (40%) patients. Female sex (83% vs. 64%; p = 0.013), arterial hypertension (47% vs. 29%; p = 0.025), arterial thrombosis at APS diagnosis (53% vs. 33%; p = 0.028), stroke (38% vs. 21%; p = 0.043), livedo reticularis (15% vs. 3%; p = 0.017), and lupus anticoagulant (83% vs. 65%; p = 0.021) were more prevalent in those with valvular involvement. Venous thrombosis was less frequent (32% vs. 50%; p = 0.042). The valve involvement group suffered from higher mortality (12% vs. 1%; p = 0.017). Most of these differences were maintained when we compared patients with moderate-to-severe valve involvement (n = 36) and those with no or mild involvement (n = 108). Conclusions: Heart valve disease is a frequent manifestation in our cohort of APS patients and is associated with demographic, clinical and laboratory features, and increased mortality. More studies are needed, but our results suggest that there may be a subgroup of APS patients with moderate-to-severe valve involvement with its own characteristics that differs from the rest of the patients with mild valve involvement or without valve involvement.

1. Introduction

The heart is one of the major target organs of antiphospholipid syndrome (APS), and valvular involvement is the most common cardiac manifestation [1], with a reported prevalence of 11.6% in large cohorts of patients with APS [2]. During the 10-year follow-up study of this cohort, 4.6% of the patients developed previously unknown thickening and/or valve dysfunction [3].
In patients with systemic lupus erythematosus (SLE) and/or APS, heart valve involvement has been related with a higher prevalence of arterial thrombotic events, mainly stroke, concomitant presence of cardiovascular risk factors, livedo reticularis, epilepsy, and migraine [4,5]. Furthermore, recent studies suggest an association between valvular involvement and a specific antiphospholipid antibodies (aPL) profile or titre [6,7,8,9,10,11,12].
In recent years, several prospective studies have analysed the evolution of valve involvement in patients with aPL [4,7,13,14,15,16]. In those performed on patients with primary APS [13,14,15], valve lesions may appear, improve, worsen, or remain unchanged over time regardless of the clinical presentation, analytical profile, or treatment.
There is no consensus on the treatment of valve involvement in APS [17]. Anticoagulation is recommended in patients with thromboembolic episodes attributed to valve disease [18]. However, this recommendation is based only in case series and not for the treatment of the valve dysfunction itself. Several studies have failed to demonstrate the efficacy of any treatment to reverse established lesions or prevent their development [4,7,11,13,14,15,16]. Although there are few case reports describing the successful treatment with corticosteroids and/or immunosuppression, currently their administration is not recommended for valve involvement [19,20].
The aim of our study was to evaluate the prevalence and type of heart valve involvement in patients with APS followed in a tertiary hospital. In addition, we analysed possible associations between valve involvement and demographics, clinical manifestations, and laboratory features.

2. Materials and Methods

In this retrospective, longitudinal, and observational study, we have included all APS patients followed in the department of Autoimmune Diseases in Hospital Clínic (Barcelona, Spain), a tertiary referral centre, from January 1980 to December 2014 in which at least one transthoracic echocardiography was performed. All patients fulfilled the current classification criteria for APS [21].
Demographic data at APS diagnosis and cardiovascular risk factors [22] were collected. Data considering APS, thrombotic manifestations, and obstetric morbidity, as well as the different clinical characteristics associated with APS but defined as non-criteria in the international consensus of 2006 [21], were also collected. The type of thrombosis (arterial, venous, and thrombotic microangiopathy) and localization were recorded. All these data were collected from the medical record of each patient and entered in a database designed specifically for this study. Time of follow-up was defined as the time (in months) from diagnosis of APS to the last visit or death.
Results of aPL determination at the APS diagnosis were included. Lupus anticoagulant (LAC) was determined following the specific recommendations of the International Society of Thrombosis and Haemostasis (ITHS) [23,24], and IgG and IgM isotypes of anticardiolipin (aCL) and antiβ2-glycoprotein I antibodies (aβ2GPI) were measured using solid-phase standardised immunoassays (ELISA). Antinuclear antibodies (ANA) were measured by indirect immunofluorescence (IIF) on rodent liver cells and/or HEp-2 cells; anti-double-stranded DNA (dsDNA) antibodies were measured by ELISA and/or IIF on Crithidia luciliae, and antibodies against extractable nuclear antigen (ENA: Ro60/SSA, La/SSB, Sm and U1-RNP) by ELISA.
We registered the first echocardiography in all patients and the last in those with valvular involvement at baseline. The echocardiographic protocol and the definitions of the main valvular findings were the same as those previously published by our group [7], where the thickness of the normal mitral and tricuspid valves was between 0.7 and 3 mm, and the normal aortic valve thickness was 0.7–2 mm. Abnormal valvular thickening was therefore considered to be present when a thickness of >3 mm (for the mitral and tricuspid valves) or >2 mm (for the aortic valve) was observed. Valvular vegetation was defined as an abnormal localised echodensity with well-defined borders that was either part of or adjacent to valve leaflets, the subvalvular apparatus, or the great vessels.
The severity stratification of valve disease was done according to the 2003 recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography, from the American Society of Echocardiography [25], and the 2017 ESC/EACTS Guidelines for the management of valvular heart disease [26].
The treatment prescribed after APS diagnosis was also recorded. During the evolution, data concerning thrombotic relapses, and/or obstetric morbidity, treatment modifications, bleeding complications, persistence of aPL profile, and outcome were collected.
The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Hospital Clinic, Barcelona (protocol code HCB/2018/1221 and date of approval 13 December 2018). Patient consent was waived due to the retrospective nature of this study.

Statistical Analysis

Categorical data are summarised as percentages; significant differences or associations were analysed using the X2 test or Fisher’s exact tests. Continuous variables are presented as mean ± standard deviation (SD) or median (interquartile range, IQR), depending on normality as demonstrated by the Kolmogorov-Smirnov test.
Associations of quantitative data were analysed with Student’s t-test and with the non-parametric Mann-Whitney U-test. A two-tailed value of p < 0.05 was taken to indicate statistical significance. Statistical analysis was performed using the SPSS program (SPSS Statistics 21.0, IBM Corp., Armonk, NY, USA).

3. Results

Overall, we identified 144 APS patients for which at least one transthoracic echocardiography was performed, representing 47.3% of the overall cohort of APS patients followed by our centre. One hundred and five patients (72.9%) suffered from primary APS; 36 (25%) had SLE-associated APS; and three (2,1%) patients had Sjögren’s syndrome.
Seventy-two (50%) patients presented with heart valve involvement. The prevalence of valve involvement was similar between primary APS patients and those with SLE (46% vs. 61%; p = 0.242). Among APS patients with valve involvement, 48 (67%) patients had primary APS; 22 had SLE (30%), and two had Sjögren’s syndrome-associated APS (3%).
The main demographic characteristics, APS-related clinical manifestations, and laboratory features according to the presence of valvular involvement are shown in Table 1 and Table 2, respectively.
In patients with valve involvement, female sex (83% vs. 64%; p = 0.013), arterial hypertension (47% vs. 29%; p = 0.025), arterial thrombosis at APS diagnosis (53% vs. 33%; p = 0.028), stroke (38% vs. 21%; p = 0.043), livedo reticularis (15% vs. 3%; p = 0.017), LAC (83% vs. 65%; p = 0.021), and double aPL positivity (61% vs. 39%; p = 0.045), were more prevalent than in patients without valve involvement. Conversely, thrombosis in venous vessels was less frequent in patients with valve involvement (32% vs. 50%; p = 0.042). Having positive ANA 81% vs. 60%; p = 0.006), low levels of C4 (29% vs. 14%; p = 0.042), and an isolated aCL as aPL profile at APS diagnosis (35% vs. 17%; p = 0.013) were the most frequent laboratory findings in the group without valvular involvement. No different frequency of valve involvement was found between primary APS or SLE-associated APS. No differences were found in the treatments received, number of thrombotic recurrences and/or the bleeding events during follow-up between the two groups (Table 1). Of note, valve involvement was associated with higher mortality (12% vs. 1%; p = 0.017). The causes of death of nine patients with heart valve involvement was a thrombosis in three of them (myocardial infarction, prosthetic mitral valve thrombosis, and cerebrovascular accident with haemorrhage). In the remaining cases, the causes of death were cardiogenic shock, alveolar haemorrhage, lymphoma, pancreatitis, septic shock of cutaneous origin, and post-surgical hemoperitoneum. The only patient without valve involvement who died presented with catastrophic APS.
In the group of APS patients with heart valve involvement, no statistically significant differences were found when comparing the demographic characteristics, cardiovascular risk factors and APS related clinical manifestations between patients with primary APS and those with SLE-associated APS.
Considering the valvular findings at the first echocardiography, mitral thickening was the most frequent abnormality that was present in 52 (72%) patients, followed by mitral regurgitation in 49 (68%), and tricuspid regurgitation in 29 (40%), respectively. In most of them, valvular regurgitation was mild (Table 3). Moreover, we found no differences in the type of valve involvement between primary APS patients and those with SLE-associated APS (Supplementary Table S1).
Of note, non-bacterial thrombotic endocarditis appeared in 26 (36%) patients, 21 of them on the mitral valve and the remaining 5 on the aortic valve. During follow-up, 12 (17%) of these patients required valvular replacement surgery, ten (83%) of the mitral valve, one (8.5%) of the aortic valve and one (8.5%) of both.
Of the patients with non-bacterial thrombotic endocarditis, four died during follow-up, one due to diffuse alveolar hemorrhage six years after the non-bacterial thrombotic endocarditis found in the initial echocardiogram had disappeared in successive echocardiograms. Another was due to valve thrombosis two months after mechanical mitral valve replacement. A third died due to cardiogenic shock 12 years after mitral valve replacement. The last one, who required a second mitral valve replacement due to prosthetic thrombosis one year after the first mechanical valve prosthesis, died five years after the last intervention due to a hemorrhagic stroke.
In addition, we compared the subgroup of patients with significant valve involvement, including those patients with moderate and severe valvular regurgitation and those with non-bacterial thrombotic endocarditis (n = 36 patients), versus those patients without valve involvement and mild valve involvement or valve thickening without functional impact (n = 108 patients) (Table 4).
Patients with significant valve involvement had a higher prevalence of arterial hypertension (56% vs. 31%; p = 0.016), and they had more arterial thrombosis (75% vs. 32%; p < 0.001), stroke (61% vs. 18%; p < 0.001), and livedo reticularis (22% vs. 5%; p = 0.019), but less venous thrombosis (11% vs. 51%; p < 0.001) and pulmonary embolism (3% vs. 18%; p = 0.026). Considering aPL profile, LAC (92% vs. 68%; p = 0.007) and double aPL positivity (75% vs. 44%; p = 0.017) were more frequent in patients with significant valve involvement, persisting in the pattern of double aPL positivity as the most frequent form of presentation. We did not find differences in the treatment they received, the number of thrombotic recurrences, the risk of bleeding, and/or mortality during follow-up between the two groups.
During follow-up, echocardiography was repeated in 40 out of 72 (57%) patients with valvular involvement at the baseline. The median number of echocardiograms per patient was three (IQR 2), and the median time between the first and last echocardiogram was 57 (IQR 77) months. Comparison of the main valvular findings between first and last echocardiograms is shown in Table 5.
Of note, tricuspid regurgitation was the only echocardiographic finding that evolved in the follow-up (increasing from 40% at initial echo to 62% at last echo; p = 0.031). However, severity remained as mild in all of them. Thirty-one (77%) patients with more than one echocardiography performed received anticoagulation after the APS diagnosis was established. The remaining nine (23%) were treated with aspirin.
The evolution of echocardiographic findings did not change regardless of the treatment received. We also found no association between follow-up time, primary or associated APS, and the type and location of thrombosis at the onset of APS with the evolution of valve involvement.
In those patients with more than one echocardiogram, we also describe the evolution of the different morphological and functional lesions, as well as the appearance of new lesions, comparing the findings between the first and last imaging tests performed. The evolutive changes of each lesion are shown in the following timeline diagrams (Figure 1, Figure 2 and Figure 3).
It is noteworthy that of the 11 patients with non-bacterial thrombotic endocarditis on the mitral valve, eight presented regressions of the lesion, disappearing completely in three of them. Of these 11 patients, 10 (91%) received anticoagulation, and only one (9%) was treated with aspirin, who remained with an unchanged thrombotic valve lesion.

4. Discussion

In the current APS international consensus of classification criteria, heart valve lesions were included as non-criteria APS manifestations in order to increase their specificity, although their association with aPL is widely recognised [21]. It is important to highlight that valvular involvement has been included in the clinical domain 5 (cardiac valve) in the new proposed ACR/EULAR Classification Criteria for APS with a different weight (two for valve thickening and four for vegetations).
The first cases and series of patients with primary APS and cardiac valve involvement date back to the early years of the 1990s [27,28,29,30,31,32,33], when two-dimensional and Doppler echocardiography studies revealed a 32% to 38% prevalence of valvular defects. Through the use of transthoracic two-dimensional and Doppler echocardiography, several studies [34,35,36,37,38] showed a significantly higher prevalence of valvular defects in SLE patients with aPLs than in those without these antibodies, while another [39] concluded that aCL antibodies either did not play a causative role or were not the only risk factors in the development of cardiac valvular vegetations.
Its therapeutic management is based on the recommendations made by an Expert Group in 2003 [18]. None of the prospective studies conducted has been able to determine clinical manifestations, laboratory features, or different treatments associated with a particular evolution of valvular involvement in APS patients [4,7,13,14,15,16]. More recently, a group of experts has prepared a consensus document with recommendations for the monitoring of these patients [40]. Its high frequency and lack of predictive factors and standardised treatment have led many authors to publish their experience in this pathology, based largely on anticoagulant therapy, immunosuppressive therapy, and valve replacement when operating parameters required it [19,20,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57].
Valve involvement in APS is characterised by valvular thickening, presence of laminar or warty thrombosis, fibrosis, and low cell infiltration. The isotype IgG of aCL and aβ2GPI and complement have been identified at the subendothelial level, and aCL IgG, IgA, and complement have been objectified at the subendothelial valve [58,59]. Therefore, that suggests a pathogenic hypothesis in which aPL would favour the formation of thrombus in valves by immune complex deposition, promoting valve damage [60].
A recent review on valve disease in autoimmune diseases [61] concluded that the prevalence of valve disease is increased in this group of patients, with thickened and fibrous valves being the most frequent findings, and mitral and aortic regurgitation as the most common sequelae. These three disorders, together with tricuspid regurgitation, are also valvular diseases in our cohort.
Some authors have found a relationship between valve involvement and/or high titres of aCL IgG [7,9,12,15]. Therefore, it has been suggested in a recent meta-analysis [62] that patients with SLE and aCL IgG positive could benefit from a screening echocardiogram. Even the presence of aCL has been associated with an increased risk of prosthetic valve thrombosis [63]. Association between cardiac valve involvement with IgA aPL and the IgG isotype of aβ2GPI against their specific domain 1 (aβ2GPI-D1) [8] or with double positive aCL/LAC patients [10] have been reported. Other studies have tried to demonstrate, with lack of association, the pathogenic role of other antibodies, such as auto-antibodies to Type I and IV collagen that have been described in rheumatic fever and infective endocarditis [64]. We have found a significant association between cardiac valve involvement and LAC, which has been associated with left ventricular diastolic dysfunction in patients with APS [65], while the presence of complement C4 fraction consumption was associated with a decreased risk of valve involvement, opening the door to another possible pathogenic pathway.
The presence of arterial thrombotic events, cardiovascular risk factors, livedo reticularis, migraine, stroke, and epilepsy has been previously described in patients with primary APS with valve involvement [4,7]. Consistent with these findings, we have found a higher frequency of arterial hypertension, a greater number of arterial thrombotic events, stroke, and the presence of livedo reticularis. At the same time, we found fewer venous thrombotic events in patients with cardiac valve involvement. When we have compared patients with moderate-to-severe valvular involvement with those with mild or no involvement, there has remained a higher prevalence of cardiovascular risk factors, as well as hypertension independently, including the presence of arterial thrombosis, stroke, livedo reticularis, and a lower frequency of venous thrombosis, deep venous thrombosis, and pulmonary embolism in those patients with moderate-to-severe valvular involvement.
The higher prevalence of arterial thrombotic events and stroke can be explained in part by the presence of atherosclerosis phenomena [66] attributable both to classic cardiovascular risk factors and the accelerated atherosclerosis itself that occurs in APS [67]. Also, valve involvement would be a risk factor for the development of cerebral embolic events. The presence of livedo reticularis is correlated histologically with endothelial proliferation, not occlusive or inflammatory [68], a phenomenon that has also been associated with early atherosclerosis [69,70]. These findings are included in the concept of APS vasculopathy, defined as proliferation and endothelial dysfunction associated with non-thrombotic manifestations associated with APS. Some authors have postulated the theory that cardiac valve involvement is another form of expression of APS-vasculopathy-affected valvular endothelial cells [4]. This theory would explain the lack of response to anticoagulant and/or anti-inflammatory therapy and its coexistence with arterial thrombotic events and livedo reticularis, two clinical manifestations that in our series also associated with cardiac valve involvement.
In patients with more than one echocardiogram, the appearance or progression of tricuspid regurgitation was the only echocardiographic finding with statistical significance but remained mild in most cases. Previously, none of the different studies [13,14,15,16] could show that the evolution of the echocardiographic findings varied according to the treatment received, and only in a cohort of SLE patients [16] was it found that the presence of APS and disease duration were independent factors for valvular disease progression. We also found no association between the evolution of valve involvement and follow-up time, primary or associated APS, and the type and location of thrombosis at the onset of APS.
The retrospective nature of our series is the main limitation of the study, as well as the inability to obtain all the data for 100% of the patients. In addition, for the classification of the degree of severity of valvular heart disease, a version prior to the 2021 ESC/EACTS Guidelines for the management of valvular heart disease has been used. However, the severity criteria remain the same in both guidelines. Another limitation is to consider valve thickening as cardiac involvement and not as a normal variant, based on the criteria previously defined by our group [7]. In this sense, we wanted to make a comparison between the group with mild valvular involvement and without valvular involvement in relation to the group with moderate and severe valvular involvement, obtaining very similar results. Although we did not find differences between patients with primary APS and those with SLE-associated APS, we did not include SLE patients without associated APS as a control group. This represents another limitation of the study in order to determine the exact role of aPL in heart valve disease. Logically, not all echocardiograms were performed by the same observer, since, in some cases, the initial echocardiogram was performed in another centre, and during 35 years of monitoring, the staff dedicated to performing echocardiography in our centre, of course, has undergone changes. However, the personnel who perform echocardiography are considered experts and are dedicated exclusively to their performance. Another factor to consider is that the review includes patients with primary APS and associated APS, so there may be an overlap of vascular involvement and early atherosclerosis not only for APS but also the associated systemic autoimmune disease, mainly systemic lupus erythematosus. Finally, echocardiographies were performed at the request of the physician in charge of the patient, and they were not done according to a pre-established protocol.
Despite the limitations described above, our results support the hypothesis of the existence of a subgroup of APS patients and cardiac valve involvement with defined clinical characteristics that could be exclusive to patients with moderate-to-severe valvular involvement. Therefore, it could be considered in the future to classify patients with APS into low heart valve risk (without involvement or with mild valve involvement and/or valve thickening) and high valve risk (moderate-to-severe valve involvement and non-bacterial thrombotic endocarditis).

5. Conclusions

Valve involvement was very frequent in our cohort of APS patients and was moderate-to-severe in 25% of them. Patients with APS and valvular involvement have their own characteristics with a higher risk of arterial thrombosis and a higher frequency of LAC. In our study, most valve lesions remained stable during follow-up. More prospective studies are needed, but our results support the hypothesis that there may be a subgroup of APS patients with moderate-to-severe valve involvement with its own characteristics that differs from the rest of the patients with APS with mild valve involvement or without valve involvement.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm12082996/s1, Table S1. Type of valve involvement between patients with primary APS and patients with SLE-associated APS.

Author Contributions

Conceptualization, I.P., M.S., B.V., G.E. and R.C.; methodology, I.P. and G.E.; formal analysis, I.P.; investigation, I.P.; data curation, I.P. and J.L.; writing—original draft preparation, I.P.; writing—review and editing, M.S., B.V., G.E. and R.C.; visualization, I.P, G.E. and R.C.; supervision, I.P. and G.E.; project administration, I.P. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Hospital Clinic, Barcelona (protocol code HCB/2018/1221 and date of approval 13 December 2018).

Informed Consent Statement

Patient consent was waived due to the retrospective nature of this study.

Data Availability Statement

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Silbiger, J.J. The cardiac manifestations of antiphospholipid syndrome and their echocardiographic recognition. J. Am. Soc. Echocardiogr. 2009, 22, 1100–1108. [Google Scholar] [CrossRef] [PubMed]
  2. Cervera, R.; Piette, J.-C.; Font, J.; Khamashta, M.A.; Shoenfeld, Y.; Camps, M.T.; Jacobsen, S.; Lakos, G.; Tincani, A.; Kontopoulou-Griva, I.; et al. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum. 2002, 46, 1019–1027. [Google Scholar] [CrossRef] [PubMed]
  3. Cervera, R.; Serrano, R.; Pons-Estel, G.J.; Ceberio-Hualde, L.; Shoenfeld, Y.; De Ramón, E.; Buonaiuto, V.; Jacobsen, S.; Zeher, M.M.; Tarr, T.; et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: A multicentre prospective study of 1000 patients. Ann. Rheum. Dis. 2015, 74, 1011–1018. [Google Scholar] [CrossRef] [PubMed]
  4. Pardos-Gea, J.; Ordi-Ros, J.; Avegliano, G.; Cortés-Hernández, J.; Balada, E.; Evangelista, A.; Vilardell, M. Echocardiography at diagnosis of antiphospholipid syndrome provides prognostic information on valvular disease evolution and identifies two subtypes of patients. Lupus 2010, 19, 575–582. [Google Scholar] [CrossRef]
  5. Krause, I.; Lev, S.; Fraser, A.; Blank, M.; Lorber, M.; Stojanovich, L.; Rovensky, J.; Chapman, J.; Shoenfeld, Y. Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome. Ann. Rheum. Dis. 2005, 64, 1490–1493. [Google Scholar] [CrossRef]
  6. Turiel, M.; Muzzupappa, S.; Gottardi, B.; Crema, C.; Sarzi-Puttini, P.; Rossi, E. Evaluation of cardiac abnormalities and embolic sources in primary antiphospholipid syndrome by transesophageal echocardiography. Lupus 2000, 9, 406–412. [Google Scholar] [CrossRef]
  7. Perez-Villa, F.; Font, J.; Azqueta, M.; Espinosa, G.; Pare, C.; Cervera, R.; Reverter, J.C.; Ingelmo, M.; Sanz, G. Severe valvular regurgitation and antiphospholipid antibodies in systemic lupus erythematosus: A prospective, long-term, followup study. Arthritis Rheum. 2005, 53, 460–467. [Google Scholar] [CrossRef]
  8. Cieśla, M.; Wypasek, E.; Undas, A. IgA Antiphospholipid Antibodies and Anti-Domain 1 of Beta 2 Glycoprotein 1 Antibodies are Associated with Livedo Reticularis and Heart Valve Disease in Antiphospholipid Syndrome. Adv. Clin. Exp. Med. 2014, 23, 729–733. [Google Scholar] [CrossRef]
  9. Djokovic, A.; Stojanovich, L.; Kontic, M.; Stanisavljevic, N.; Radovanovic, S.; Marisavljevic, D. Association between cardiac manifestations and antiphospholipid antibody type and level in a cohort of Serbian patients with primary and secondary antiphospholipid syndrome. Isr. Med. Assoc. J. 2014, 16, 162–167. [Google Scholar]
  10. Vivero, F.; Gonzalez-Echavarri, C.; Ruiz-Estevez, B.; Maderuelo, I.; Ruiz-Irastorza, G. Prevalence and predictors of valvular heart disease in patients with systemic lupus erythematosus. Autoimmun. Rev. 2016, 15, 1134–1140. [Google Scholar] [CrossRef]
  11. Ruiz, D.; Oates, J.C.; Kamen, D.L. Antiphospholipid Antibodies and Heart Valve Disease in Systemic Lupus Erythematosus. Am. J. Med. Sci. 2018, 355, 293–298. [Google Scholar] [CrossRef] [PubMed]
  12. Zuily, S.; Regnault, V.; Selton-Suty, C.; Eschwège, V.; Bruntz, J.F.; Bode-Dotto, E.; De Maistre, E.; Dotto, P.; Perret-Guillaume, C.; Lecompte, T.; et al. Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: Meta-analysis of echocardiographic studies. Circulation 2011, 124, 215–224. [Google Scholar] [CrossRef] [PubMed]
  13. Espínola-Zavaleta, N.; Vargas-Barrón, J.; Colmenares-Galvis, T.; Cruz-Cruz, F.; Romero-Cárdenas, A.; Keirns, C.; Amigo, M.-C. Echocardiographic evaluation of patients with primary antiphospholipid syndrome. Am. Heart J. 1999, 137, 973–978. [Google Scholar] [CrossRef] [PubMed]
  14. Zavaleta, N.E.; Montes, R.M.; Soto, M.E.; Vanzzini, N.A.; Amigo, M.C. Primary antiphospholipid syndrome: A 5-year transesophageal echocardiographic followup study. J. Rheumatol. 2004, 31, 2402–2407. [Google Scholar]
  15. Turiel, M.; Sarzi-Puttini, P.; Peretti, R.; Bonizzato, S.; Muzzupappa, S.; Atzeni, F.; Rossi, E.; Doria, A. Five-year follow-up by transesophageal echocardiographic studies in primary antiphospholipid syndrome. Am. J. Cardiol. 2005, 96, 574–579. [Google Scholar] [CrossRef]
  16. Kampolis, C.; Tektonidou, M.; Moyssakis, I.; Tzelepis, G.E.; Moutsopoulos, H.; Vlachoyiannopoulos, P.G. Evolution of cardiac dysfunction in patients with antiphospholipid antibodies and/or antiphospholipid syndrome: A 10-year follow-up study. Semin. Arthritis Rheum. 2014, 43, 558–565. [Google Scholar] [CrossRef]
  17. Espinosa, G.; Cervera, R. Current treatment of antiphospholipid syndrome: Lights and shadows. Nat. Rev. Rheumatol. 2015, 11, 586–596. [Google Scholar] [CrossRef]
  18. Xourgia, E.; Tektonidou, M.G. Management of Non-criteria Manifestations in Antiphospholipid Syndrome. Curr. Rheumatol. Rep. 2020, 22, 51. [Google Scholar] [CrossRef]
  19. Andrade, D.; Tektonidou, M. Emerging Therapies in Antiphospholipid Syndrome. Curr. Rheumatol. Rep. 2016, 18, 22. [Google Scholar] [CrossRef]
  20. Sevim, E.; Willis, R.; Erkan, D. Is there a role for immunosuppression in antiphospholipid syndrome? Hematol. Am. Soc. Hematol. Educ. Program 2019, 2019, 426–432. [Google Scholar] [CrossRef] [PubMed]
  21. Miyakis, S.; Lockshin, M.D.; Atsumi, T.; Branch, D.W.; Brey, R.L.; Cervera, R.; Derksen, R.H.; DE Groot, P.G.; Koike, T.; Meroni, P.L.; et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 2006, 4, 295–306. [Google Scholar] [CrossRef] [PubMed]
  22. D’Agostino Sr, R.B.; Vasan, R.S.; Pencina, M.J.; Wolf, P.A.; Cobain, M.; Massaro, J.M.; Kannel, W.B. General cardiovascular risk profile for use in primary care: The Framingham Heart Study. Circulation 2008, 117, 743–753. [Google Scholar] [CrossRef] [PubMed]
  23. Devreese, K.M.J.; de Groot, P.G.; de Laat, B.; Erkan, D.; Favaloro, E.J.; Mackie, I.; Martinuzzo, M.; Ortel, T.L.; Pengo, V.; Rand, J.H.; et al. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation. J. Thromb. Haemost. 2020, 18, 2828–2839. [Google Scholar] [CrossRef] [PubMed]
  24. Cohen, H.; Mackie, I.J.; Devreese, K.M.J.; International Society for Thrombosis and Haemostasis Scientific and Standardization Committee for Lupus Anticoagulant/Antiphospholipid Antibodies. Clinical and laboratory practice for lupus anticoagulant testing: An International Society of Thrombosis and Haemostasis Scientific and Standardization Committee survey. J. Thromb. Haemost. 2019, 17, 1715–1732. [Google Scholar] [CrossRef] [PubMed]
  25. Zoghbi, W.A.; Enriquez-Sarano, M.; Foster, E.; Grayburn, P.A.; Kraft, C.D.; Levine, R.A.; Nihoyannopoulos, P.; Otto, C.M.; Quinones, M.A.; Rakowski, H.; et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J. Am. Soc. Echocardiogr. 2003, 16, 777–802. [Google Scholar] [CrossRef]
  26. Falk, V.; Baumgartner, H.; Bax, J.J.; De Bonis, M.; Hamm, C.; Holm, P.J.; Iung, B.; Lancellotti, P.; Lansac, E.; Muñoz, D.R.; et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur. J. Cardiothorac. Surg. 2017, 52, 616–664. [Google Scholar] [CrossRef]
  27. Vianna, J.L.; Khamashta, M.A.; Ordi-Ros, J.; Font, J.; Cervera, R.; Lopez-Soto, A.; Tolosa, C.; Franz, J.; Selva-O’Callaghan, A.; Ingelmo, M.; et al. Comparison of the primary and secondary antiphospholipid syndrome: A European Multicenter Study of 114 patients. Am. J. Med. 1994, 96, 3–9. [Google Scholar] [CrossRef]
  28. Barbut, D.; Borer, J.S.; Wallerson, D.; Ameisen, O.; Lockshin, M. Anticardiolipin antibody and stroke: Possible relation of valvular heart disease and embolic events. Cardiology 1991, 79, 99–109. [Google Scholar] [CrossRef]
  29. Kalashnikova, L.A.; Nasonov, E.L.; Borisenko, V.V.; Usman, V.B.; Prudnikova, L.Z.; Kovaljov, V.U.; Kushekbaeva, A.F. Sneddon’s syndrome: Cardiac pathology and antiphospholipid antibodies. Clin. Exp. Rheumatol. 1991, 9, 357–361. [Google Scholar]
  30. Font, J.; Carvera, R.; Parè, C.; Lòpez-Soto, A.; Pallarès, L.; Azqueta, M.; Khamashta, M.A. Non-infective verrucous endocarditis in a patient with ‘primary’ antiphospholipid syndrome. Br. J. Rheumatol. 1991, 30, 305–307. [Google Scholar] [CrossRef] [PubMed]
  31. Brenner, B.; Blumenfeld, Z.; Markiewicz, W.; Reisner, S.A. Cardiac involvement in patients with primary antiphospholipid syndrome. J. Am. Coll. Cardiol. 1991, 18, 931–936. [Google Scholar] [CrossRef] [PubMed]
  32. Cervera, R.; Khamashta, M.A.; Font, J.; Reyes, P.A.; Vianna, J.L.; López-Soto, A.; Amigo, M.-C.; Asherson, R.A.; Azqueta, M.; Paré, C.; et al. High prevalence of significant heart valve lesions in patients with the ‘primary’ antiphospholipid syndrome. Lupus 1991, 1, 43–47. [Google Scholar] [CrossRef] [PubMed]
  33. Galve, E.; Ordi, J.; Barquinero, J.; Evangelista, A.; Vilardell, M.; Soler-Soler, J. Valvular heart disease in the primary antiphospholipid syndrome. Ann. Intern. Med. 1992, 116, 293–298. [Google Scholar] [CrossRef]
  34. Khamashta, M.A.; Cervera, R.; Asherson, R.A.; Font, J.; Gil, A.; Coltart, D.J.; Vázquez, J.J.; Paré, C.; Ingelmo, M.; Oliver, J.; et al. Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus. Lancet 1990, 335, 1541–1544. [Google Scholar] [CrossRef] [PubMed]
  35. Nihoyannopoulos, P.; Gomez, P.M.; Joshi, J.; Loizou, S.; Walport, M.J.; Oakley, C.M. Cardiac abnormalities in systemic lupus erythematosus. Association with raised anticardiolipin antibodies. Circulation 1990, 82, 369–375. [Google Scholar] [CrossRef] [PubMed]
  36. Cervera, R.; Font, J.; Paré, C.; Azqueta, M.; Pérez-Villa, F.; López-Soto, A.; Ingelmo, M. Cardiac disease in systemic lupus erythematosus: Prospective study of 70 patients. Ann. Rheum. Dis. 1992, 51, 156–159. [Google Scholar] [CrossRef] [PubMed]
  37. Jouhikainen, T.; Pohjola-Sintonen, S.; Stephansson, E. Lupus anticoagulant and cardiac manifestations in systemic lupus erythematosus. Lupus 1994, 3, 167–172. [Google Scholar] [CrossRef]
  38. Leung, W.H.; Wong, K.L.; Lau, C.P.; Wong, C.K.; Liu, H.W. Association between antiphospholipid antibodies and cardiac abnormalities in patients with systemic lupus erythematosus. Am. J. Med. 1990, 89, 411–419. [Google Scholar] [CrossRef]
  39. Gleason, C.B.; Stoddard, M.F.; Wagner, S.G.; A Longaker, R.; Pierangeli, S.; Harris, E. A comparison of cardiac valvular involvement in the primary antiphospholipid syndrome versus anticardiolipin-negative systemic lupus erythematosus. Am. Heart J. 1993, 125, 1123–1129. [Google Scholar] [CrossRef]
  40. Cervera, R.; Tektonidou, M.; Espinosa, G.; Cabral, A.R.; González, E.B.; Erkan, D.; Vadya, S.; E Adrogué, H.; Solomon, M.; Zandman-Goddard, G.; et al. Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (I): Catastrophic APS, APS nephropathy and heart valve lesions. Lupus 2011, 20, 165–173. [Google Scholar] [CrossRef]
  41. Granowicz, E.; Chung, K. Improvement of Cardiac Vegetations in Antiphospholipid Syndrome with Enoxaparin and Corticosteroids after Rivaroxaban Failure. Case Rep. Hematol. 2018, 2018, 8097539. [Google Scholar] [CrossRef] [PubMed]
  42. Yuriditsky, E.; Torres, J.; Izmirly, P.M.; Belmont, H.M. Resolution of large aortic valve vegetations in antiphospholipid syndrome treated with therapeutic anticoagulation: A report of two cases and literature review. Lupus 2018, 27, 2269–2273. [Google Scholar] [CrossRef] [PubMed]
  43. Thomas, L.M.; Shaikh, N.A.; Pradeep, R. An extraordinary case of recurrent stroke, disseminated thrombosis and endocarditis. BMJ Case Rep. 2018, 2018, bcr2018224172. [Google Scholar] [CrossRef] [PubMed]
  44. Mahajan, K.; Negi, P.; Merwaha, R.; Sharma, M. Isolated tricuspid valve Libman-Sacks endocarditis in a patient with antiphospholipid antibody syndrome. BMJ Case Rep. 2017, 2017, bcr2017219217. [Google Scholar] [CrossRef] [PubMed]
  45. Arif, R.; Farag, M.; Seppelt, P.; Beller, C.J.; Ruhparwar, A.; Karck, M.; Kallenbach, K. Patients with systemic lupus erythematosus and antiphospholipid syndrome undergoing cardiac valve surgery. J. Heart Valve Dis. 2015, 24, 228–235. [Google Scholar]
  46. Bai, Z.; Hou, J.; Ren, W.; Guo, Y. Diagnosis and surgical treatment for isolated tricuspid Libman-Sacks endocarditis: A rare case report and literatures review. J. Cardiothorac. Surg. 2015, 10, 93. [Google Scholar] [CrossRef]
  47. Hachiya, K.; Wakami, K.; Tani, T.; Yoshida, A.; Suzuki, S.; Suda, H.; Ohte, N. Double-valve replacement for mitral and aortic regurgitation in a Patient with Libman-Sacks endocarditis. Intern. Med. 2014, 53, 1769–1773. [Google Scholar] [CrossRef]
  48. Correia, M.; Silva, A.; Mota-Garcia, R.; Mendes, S.; Martins, L.; Santos, M. An unusual case of pacemaker endocarditis in a patient with antiphospholipid syndrome. Rev. Port. Cardiol. 2012, 31, 309–312. [Google Scholar] [CrossRef]
  49. Teunisse, C.C.; Kalsbeek, A.J.; De Vries, S.T.; Huisman, S.J.; E Boers, J.; Breeman, A.; Beukhof, J.R. Reversible cardiac valvular disease in catastrophic antiphospholipid syndrome. Neth. J. Med. 2010, 68, 215–220. [Google Scholar]
  50. Bhimani, A.A.; Hoit, B.D. Extensive nonbacterial thrombotic endocarditis isolated to the tricuspid valve in primary antiphospholipid syndrome. J. Am. Soc. Echocardiogr. 2010, 23, 107.e5–107.e6. [Google Scholar] [CrossRef]
  51. Salzberg, S.P.; Nemirovsky, D.; Goldman, M.E.; Adams, D.H. Aortic valve vegetation without endocarditis. Ann. Thorac. Surg. 2009, 88, 267–269. [Google Scholar] [CrossRef] [PubMed]
  52. Ruan, Y.; Bridges, J.S.; Kumar, K.; Raphael, J.A.; Acharjee, S.; Welty, F.K. Complete resolution of a mitral valve vegetation with anticoagulation in seronegative antiphospholipid syndrome. Clin. Rheumatol. 2008, 27, 1577–1579. [Google Scholar] [CrossRef] [PubMed]
  53. Lønnebakken, M.T.; Gerdts, E. Libman-Sacks endocarditis and cerebral embolization in antiphospholipid syndrome. Eur. J. Echocardiogr. 2008, 9, 192–193. [Google Scholar] [CrossRef]
  54. Sasahashi, N.; Harada, H.; Saji, Y.; Marui, A.; Nishina, T.; Komeda, M. Aortic valve replacement for aortic regurgitation in a patient with antiphospholipid antibody syndrome. Gen. Thorac. Cardiovasc. Surg. 2007, 55, 293–296. [Google Scholar] [CrossRef] [PubMed]
  55. Falode, O.; Hunt, I.; Chambers, J.; Blauth, C. Large tricuspid mass in primary antiphospholipid syndrome. Ann. Thorac. Surg. 2006, 82, 1538. [Google Scholar] [CrossRef] [PubMed]
  56. Letsas, K.P.; Filippatos, G.S.; Kounas, S.P.; Pappas, L.K.; Kardaras, F.; Gavrielatos, G. Primary antiphospholipid syndrome and factor V Leiden mutation in a young patient with non-bacterial thrombotic endocarditis and transient ischemic stroke. Thromb. Haemost. 2005, 94, 1331–1332. [Google Scholar] [CrossRef] [PubMed]
  57. Gonzalez-Juanatey, C.; Gonzalez-Gay, M.A. Libman-sacks endocarditis and primary antiphospholipid syndrome. J. Heart Valve Dis. 2005, 14, 700–702. [Google Scholar]
  58. Kolitz, T.; Shiber, S.; Sharabi, I.; Winder, A.; Zandman-Goddard, G. Cardiac Manifestations of Antiphospholipid Syndrome With Focus on Its Primary Form. Front. Immunol. 2019, 10, 941. [Google Scholar] [CrossRef]
  59. Ziporen, L.; Goldberg, I.; Arad, M.; Hojnik, M.; Ordi-Ros, J.; Afek, A.; Blank, M.; Sandbank, Y.; Vilardell-Tarres, M.; de Torres, I.; et al. Libman-Sacks endocarditis in the antiphospholipid syndrome: Immunopathologic findings in deformed heart valves. Lupus 1996, 5, 196–205. [Google Scholar] [CrossRef]
  60. Amigo, M.C.; García-Torres, R. Morphology of vascular, renal, and heart lesions in the antiphospholipid syndrome: Relationship to pathogenesis. Curr. Rheumatol. Rep. 2000, 2, 262–270. [Google Scholar] [CrossRef]
  61. Gartshteyn, Y.; Bhave, N.; Joseph, M.S.; Askanase, A.; Bernstein, E.J. Inflammatory and thrombotic valvulopathies in autoimmune disease. Heart 2022, 109, 583–588. [Google Scholar] [CrossRef]
  62. Hussain, K.; Gauto-Mariotti, E.; Cattoni, H.M.; Arif, A.W.; Richardson, C.; Manadan, A.; Yadav, N. A Meta-analysis and Systematic Review of Valvular Heart Disease in Systemic Lupus Erythematosus and Its Association with Antiphospholipid Antibodies. J. Clin. Rheumatol. 2021, 27, e525–e532. [Google Scholar] [CrossRef] [PubMed]
  63. Aykan, A.Ç.; Gökdeniz, T.; Kalçık, M.; Astarcıoğlu, M.A.; Gündüz, S.; Karakoyun, S.; Gürsoy, M.O.; Oğuz, A.E.; Ertürk, E.; Çakal, B.; et al. Role of anticardiolipin antibodies in the pathogenesis of prosthetic valve thrombosis: An observational study. Herz 2015, 40, 528–533. [Google Scholar] [CrossRef] [PubMed]
  64. Pardos-Gea, J.; Cortés-Hernández, J.; Castro-Marrero, J.; Balada, E.; Ordi-Ros, J. Autoantibodies to types I and IV collagen and heart valve disease in systemic lupus erythematosus/antiphospholipid syndrome. Clin. Rheumatol. 2017, 36, 1401–1406. [Google Scholar] [CrossRef] [PubMed]
  65. Tufano, A.; Lembo, M.; Di Minno, M.N.; Nardo, A.; Esposito, R.; Santoro, C.; Buonauro, A.; Cerbone, A.M.; Di Minno, G.; Galderisi, M. Left ventricular diastolic abnormalities other than valvular heart disease in antiphospholipid syndrome: An echocardiographic study. Int. J. Cardiol. 2018, 271, 366–370. [Google Scholar] [CrossRef]
  66. Erkan, D.; Yazici, Y.; Peterson, M.G.; Sammaritano, L.; Lockshin, M.D. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology 2002, 41, 924–929. [Google Scholar] [CrossRef]
  67. Belizna, C.C.; Richard, V.; Primard, E.; Kerleau, J.M.; Cailleux, N.; Louvel, J.P.; Marie, I.; Hamidou, M.; Thuillez, C.; Lévesque, H. Early atheroma in primary and secondary antiphospholipid syndrome: An intrinsic finding. Semin. Arthritis Rheum. 2008, 37, 373–380. [Google Scholar] [CrossRef]
  68. Lewandowska, E.; Wierzba-Bobrowicz, T.; Wagner, T.; Bogusławska, R.; Rudnicka, A.; Leszczyńska, A.; Pasennik, E.; Lechowicz, W.; Stepień, T.; Kuran, W. Sneddon’s syndrome as a disorder of small arteries with endothelial cells proliferation: Ultrastructural and neuroimaging study. Folia Neuropathol. 2005, 43, 345–354. [Google Scholar]
  69. Christodoulou, C.; Sangle, S.; D’Cruz, D.P. Vasculopathy and arterial stenotic lesions in the antiphospholipid syndrome. Rheumatology 2007, 46, 907–910. [Google Scholar] [CrossRef]
  70. Der, H.; Kerekes, G.; Veres, K.; Szodoray, P.; Toth, J.; Lakos, G.; Szegedi, G.; Soltesz, P. Impaired endothelial function and increased carotid intima-media thickness in association with elevated von Willebrand antigen level in primary antiphospholipid syndrome. Lupus 2007, 16, 497–503. [Google Scholar] [CrossRef] [PubMed]
Jcm 12 02996 g001 550
Figure 1. Timeline diagram with evolutive changes of mitral valve involvement.
Figure 1. Timeline diagram with evolutive changes of mitral valve involvement.
Jcm 12 02996 g001
Jcm 12 02996 g002 550
Figure 2. Timeline diagram with evolutive changes of aortic and tricuspid valve involvement.
Figure 2. Timeline diagram with evolutive changes of aortic and tricuspid valve involvement.
Jcm 12 02996 g002
Jcm 12 02996 g003 550
Figure 3. Timeline diagram with evolutive changes of normal valves. * More than one valvular lesion or dysfunction occurred in the same patient. Abbreviations: NBTE: non-bacterial thrombotic endocarditis.
Figure 3. Timeline diagram with evolutive changes of normal valves. * More than one valvular lesion or dysfunction occurred in the same patient. Abbreviations: NBTE: non-bacterial thrombotic endocarditis.
Jcm 12 02996 g003
Table
Table 1. Demographic characteristics, cardiovascular risk factors and APS related clinical manifestations of patients with APS according to the presence of heart valve involvement detected by echocardiography.
Table 1. Demographic characteristics, cardiovascular risk factors and APS related clinical manifestations of patients with APS according to the presence of heart valve involvement detected by echocardiography.
With Valve Involvement
(n = 72)
N (%)		Without Valve Involvement
(n = 72)
N (%)		p
Sex (F/M)60/12 (83/17)46/26 (64/36)0.013
Age at APS diagnosis (years)41.2 ± 15.141 ± 13.90.699
Follow-up (months)115.3 ± 57.6104.6 ± 61.20.213
TTE made at time of APS diagnosis30 (42)23 (32)0.275
Primary APS48 (67)57 (80)0.133
SLE associated APS22 (30)14 (19)0.177
Cardiovascular risk factors a
 Current smoking21/68 (31)14/69 (20)0.112
 Ever smoking16/68 (31)22/69 (32)0.260
 Arterial hypertension34 (47)20 (28)0.025
 Dyslipidemia14 (19)17 (24)0.686
 Diabetes mellitus5 (7)3 (4)0.719
 Hormonal contraceptives use7/60 (12)8/46 (17)0.196
APS-related clinical manifestations
 Thrombosis63 (88)60 (83)0.638
  Arterial38 (53)24 (33)0.028
  Venous23 (32)36 (50)0.042
  Both3 (4)4 (7)1.000
 Peripheral DVT17 (24)27 (37)1.000
 Pulmonary embolism6 (8)15 (21)0.057
 Ischemic heart disease4 (6)3 (4)1.000
 Stroke27 (38)15 (21)0.043
 Transient ischemic attack3 (4)4 (6)1.0000
 Cerebral silent ischemia4 (6)3 (4)0.439
 Epilepsy6 (8)3 (4)0.494
 Migraine10 (14)8 (11)0.802
 Multiinfarct dementia3 (4)2 (3)1.000
 Obstetric morbidity b37/60 (62)21/46 (46) 0.681
 Livedo reticularis11 (15)2 (3)0.017
 Cutaneous ulcers1 (1)3 (4)0.620
 Thrombocytopenia c22 (31)15 (21)0.252
 Hemolytic anemia3 (4)4 (6)1.000
 Renal thrombotic microangiopathy5 (7)2 (3)0.719
 Optic neuritis4 (6)3 (4)1.000
 Retinal veno-occlusive disease1 (1)1 (1)1.000
 Central retinal artery thrombosis2 (3)0 (0)0.497
 Central retinal vein thrombosis1 (4)1 (1)1.000
Thrombotic relapse d 22/52 (42)11/46 (25)0.858
Hemorrhagic events d11/52 (21)9/46 (20)0.810
Death9 (12)1 (1)0.017
a Including any of those described in the table; b Including abortions and fetal losses; c defined as platelet count < 100 × 109/L; d under anticoagulant treatment. Values of categorical variables are expressed as number and percentage and those for continuous variables are presented as mean ± standard deviation. Abbreviations: APS: antiphospholipid syndrome; DVT: deep venous thrombosis; F: female; M: male; SLE: systemic lupus erythematosus; TTE: transthoracic echocardiography.
Table
Table 2. Laboratory features of patients with antiphospholipid syndrome according to the presence of heart valve involvement detected by echocardiography.
Table 2. Laboratory features of patients with antiphospholipid syndrome according to the presence of heart valve involvement detected by echocardiography.
With Valve
Involvement
(n = 72)
N (%)		Without Valve
Involvement
(n = 72)
N (%)		p
LAC60 (83)47 (65)0.021
aCL56 (78)56 (78)1.000
 IgG aCL47 (65)44/57 (77)1.000
 IgM aCL26 (36)21/58 (36)0.348
aβ2GPI14/40 (35)12/43 (28)0.473
 IgG aβ2GPI 10/40 (25)5/13 (38)1.000
 IgM aβ2GPI 10/40 (25)8/13 (61)0.255
aPL profile at APS diagnosis
 Isolated LAC14 (19)13 (18)0.414
 Isolated aCL12 (17)26 (36)0.013
 Isolated aβ2GPI1/40 (2)1/43 (2)1.000
 Double positivity44 (61)28 (39)0.045
 Triple positivity1 (1)2 (3)1.000
ANA43 (60)58 (81)0.006
 Anti-dsDNA abs20 (28)23 (32)0.716
 Anti-Ro abs5 (7)8 (11)0.400
 Anti-La abs3 (4)3 (4)1.000
 Anti-Sm abs2 (3)1 (1)1.000
 Anti-U1-RNP abs4 (6)5 (7)0.745
Low levels of C313 (18)15 (21)0.834
Low levels of C410 (14)21 (29)0.042
Including any combination of aPL (LAC plus aCL or aCL plus aβ2GPI or LAC plus aβ2GPI). Abbreviations: aCL: anticardiolipin antibodies; aβ2GPI: anti-β2 glycoprotein I antibodies; ANA: antinuclear antibodies; aPL: antiphospholipid antibodies; APS: antiphospholipid syndrome; LAC: lupus anticoagulant.
Table
Table 3. Prevalence of valvular abnormalities on the first transthoracic echocardiography in patients with antiphospholipid syndrome.
Table 3. Prevalence of valvular abnormalities on the first transthoracic echocardiography in patients with antiphospholipid syndrome.
Heart Valve InvolvementFirst Echocardiography
(n = 72)
N (%)
Mitral valve
 Mitral thickening52 (72)
 Mitral regurgitation49 (68)
  Mild33 (67)
  Moderate10 (21)
  Severe6 (12)
 Mitral stenosis1 (1)
 Non-infectious thrombotic mitral endocarditis *21 (29)
Aortic valve
 Aortic thickening18 (25)
 Aortic regurgitatiom16 (22)
  Mild9 (56)
  Moderate6 (38)
  Severe1 (6)
 Aortic stenosis2 (3)
 Non-infectious thrombotic aortic endocarditis *5 (7)
Tricuspid valve
Tricuspid thickening1 (1)
 Tricuspid regurgitation29 (40)
  Mild29 (100)
  Moderate0
  Severe0
* Also included non-bacterial thrombotic endocarditis that appeared during follow-up.
Table
Table 4. Comparison between group with moderate and severe valve involvement versus group without valve involvement and/or with mild involvement or valve thickening without functional impact.
Table 4. Comparison between group with moderate and severe valve involvement versus group without valve involvement and/or with mild involvement or valve thickening without functional impact.
Significative Valve Involvement
N (%)
(n = 36)		Without or Mild Valve Involvement
N (%)
(n = 108)		p
Cardiovascular risk factors
 Arterial hypertension20 (56)34 (31)0.016
APS-related clinical manifestations
 Thrombosis32 (89)91 (84)0.595
  Arterial26 (75)36 (32)<0.001
  Venous4 (11)55 (51)<0.001
 Peripheral DVT4 (11)40 (37)0.003
 Pulmonary embolism1 (3)20 (18)0.026
 Stroke21 (61)21 (18)<0.001
 Livedo reticularis7 (22)6 (5)0.019
Laboratory features
 LAC33 (92)74 (68)0.007
 aPL profile at APS diagnosis
  Isolated LAC5 (11)22 (20)0.137
  Isolated aCL4 (11)34 (31)0.346
  Isolated aβ2GPI0 (0)2 (2)1.000
  Double positivity27 (75)49 (44)0.032
  Triple positivity1 (3)2 (2)0.486
Includes any combination of aPL (LAC plus aCL or aCL plus aβ2GPI or LAC plus aβ2GPI). Abbreviations: aβ2GPI: anti-β2 glycoprotein I antibodies; aCL: anticardiolipin antibodies; aPL: antiphospholipid antibodies; APS: antiphospholipid syndrome; LAC: lupus anticoagulant.
Table
Table 5. Comparison of heart valve involvement between first and last echocardiograms.
Table 5. Comparison of heart valve involvement between first and last echocardiograms.
Initial EchocardiogramPatients
(n = 40)		Follow-Up EchocardiogramPatients
(n = 40)		p
Mitral valve Mitral valve
Thickening33 (82)Thickening32 (80)0.711
Regurgitation31 (77)Regurgitation32 (80)0.628
 Mild19/31 (61) Mild15/32 (47)
 Moderate10/31 (32) Moderate12/32 (37)
 Severe2/31 (6) Severe5/32 (16)
Aortic valve Aortic valve
Thickening7 (17)Thickening8 (20)0.660
Regurgitation9 (22)Regurgitation10 (25)0.660
 Mild5/9 (56) Mild9/10 (90)
 Moderate4/9 (44) Moderate1/10 (10)
 Severe0/9 (0) Severe0/10 (0)
Stenosis1 (2)Stenosis3 (7)0.323
Tricuspid valve Tricuspid valve
Thickening0 (0)Thickening1 (2)0.323
Regurgitation16 (40)Regurgitation24 (62)0.031
 Mild16/16 (100) Mild24/24 (100)
 Moderate0/16 (0) Moderate0/24 (0)
 Severe0/16 (0) Severe0/24 (0)
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Pons, I.; Louro, J.; Sitges, M.; Vidal, B.; Cervera, R.; Espinosa, G. Heart Valve Involvement in Patients with Antiphospholipid Syndrome: A Long-Term Follow-Up Study of a Single Centre. J. Clin. Med. 2023, 12, 2996. https://doi.org/10.3390/jcm12082996

AMA Style

Pons I, Louro J, Sitges M, Vidal B, Cervera R, Espinosa G. Heart Valve Involvement in Patients with Antiphospholipid Syndrome: A Long-Term Follow-Up Study of a Single Centre. Journal of Clinical Medicine. 2023; 12(8):2996. https://doi.org/10.3390/jcm12082996

Chicago/Turabian Style

Pons, Isaac, Joana Louro, Marta Sitges, Bàrbara Vidal, Ricard Cervera, and Gerard Espinosa. 2023. "Heart Valve Involvement in Patients with Antiphospholipid Syndrome: A Long-Term Follow-Up Study of a Single Centre" Journal of Clinical Medicine 12, no. 8: 2996. https://doi.org/10.3390/jcm12082996

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop